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Abstract
Proteolipid protein 2 (PLP2) is an integral ion channel membrane protein of the en-
doplasmic reticulum. The protein has been shown to be highly expressed in many 
cancer types, but its importance in glioma progression is poorly understood. Using 
publicly available datasets (Rembrandt, TCGA and CGGA), we found that the ex-
pression of PLP2 was significantly higher in high-grade gliomas than in low-grade 
gliomas. We confirmed these results at the protein level through IHC staining of high-
grade (n = 56) and low-grade glioma biopsies (n = 16). Kaplan-Meier analysis demon-
strated that increased PLP2 expression was associated with poorer patient survival. 
In functional experiments, siRNA and shRNA PLP2 knockdown induced ER stress 
and increased apoptosis and autophagy in U87 and U251 glioma cell lines. Inhibition 
of autophagy with chloroquine augmented apoptotic cell death in U87- and U251-
siPLP2 cells. Finally, intracranial xenografts derived from U87- and U251-shPLP2 
cells revealed that loss of PLP2 reduced glioma growth in vivo. Our results therefore 
indicate that increased PLP2 expression promotes GBM growth and that PLP2 rep-
resents a potential future therapeutic target.
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1  | INTRODUC TION
Gliomas constitute approximately 75% of the malignant primary 
brain tumours in adults.1 The life expectancy of patients with glio-
blastoma (GBM, WHO grade IV) is on average 14 months after di-
agnosis, and current treatment strategies have shown only limited 
survival benefits.2 Consequently, a deeper understanding of the 
mechanisms underlying glioma growth and progression is important 
in order to develop new therapeutic strategies.
The proteolipid protein 2 (PLP2) gene, also known as A4/A4LSB, 
was first discovered in colon epithelial cells. While the exact func-
tion of PLP2 under normal conditions is not known, the study 
of the protein has revealed several features. First, it is an integral 
membrane protein that localizes to the endoplasmic reticulum (ER). 
Second, it has been shown to multimerize and to exhibit ion chan-
nel characteristics.3 Third, PLP2-knockout mice display increased 
ER stress in neurons under hypoxia, which leads to apoptotic cell 
death.7 Finally, PLP2 might have a role in normal gastrulation.8 PLP2 
has also been reported to be involved in disease. In several cancers, 
for example, such as melanoma, breast cancer and osteogenic sar-
coma, the protein has been shown to promote cell growth, prolifer-
ation and migration.4-6
Around one-third of the total proteome is synthesized in the ER 
which is the dominating subcellular compartment involved in pro-
tein folding and maturation.9,10 Various physiological and patholog-
ical stimuli can alter ER function, which leads to ER stress. In many 
instances, ER stress leads to an accumulation of unfolded or mis-
folded proteins inside the ER. For instance, ER stress can cause an 
unfolded protein response (UPR). Unfolded protein response is an 
adaptive reaction to reduce the unfolded protein load in order to 
maintain cellular viability and function.11 Therefore, under ER stress, 
the accumulation of misfolded proteins triggers UPR, which leads 
to an activation of biochemical mechanisms alleviating ER stress. If 
homeostasis cannot be restored by UPR, autophagy or apoptotic cell 
death may be activated.12,13
Autophagy is involved in the delivery of unwanted cytoplasmic 
cargo to the lysosomes for subsequent degradation within auto-
phagosomes. It is essential for survival and homeostasis and may 
F I G U R E  1   PLP2 expression is up-
regulated in high-grade gliomas and 
inversely associated with glioblastoma 
patient prognosis. A, Relative 
expression levels of PLP2 mRNA in 
samples analysed in publicly available 
databases REMBRANDT, TCGA and 
CGGA. Ns, not significant, *P < .05 and 
***P < .001. B, Representative images 
of immunohistochemical staining for 
PLP2 in 4-µm sections from normal 
brain tissue samples (NBT), grade II 
gliomas (II), grade III gliomas (III) and 
glioblastomas (IV). Scale bar = 100 μm. C, 
Immunohistochemical scores for PLP2 in 
normal brain tissue samples (NBT), grade 
II gliomas (II), grade III gliomas (III) and 
glioblastomas (IV). Five random fields 
from each section were counted. Data 
are shown as the mean ± SD. *P < .05, 
**P < .01 and ***P < .001. D, Western blot 
analysis of PLP2 levels in NHA, U87, A172, 
U251 and T98 cell lines. E, Kaplan-Meier 
analyses showing differences in overall 
survival for patients with low and high 
PLP2 expressing gliomas. The data were 
obtained from Rembrandt, TCGA and 
CGGA databases
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mediate resistance to anticancer therapies such as radiation, chemo-
therapy and targeted therapies.14,15 However, the role of autophagy 
in cancer is still inconclusive, since under some conditions, autoph-
agy suppresses tumorigenesis,16 whereas in others, it facilitates tu-
mour growth.17
Apoptosis is a highly regulated form of programmed cell death. 
A better understanding of the signalling pathways that control 
apoptosis in different tumour types has been important for the 
discovery of novel targeted agents and for the design of clinical 
trials.18,19 As a result, apoptosis and the induction of autophagy, 
and in particular the crosstalk between these two processes, re-
main a subject of interest.
In the present study, we show in both clinical samples and cell 
lines that PLP2 is significantly overexpressed in GBMs compared 
with normal human astrocytes (NHAs) and normal human brain tis-
sue samples. We investigated the significance of this finding through 
PLP2 knockdown in U87 and U251 glioma cell lines in vitro and in 
vivo. We found that PLP2 knockdown reduces cell proliferation and 
increases ER stress-induced apoptosis and autophagy via CCAAT-
enhancer-binding protein homologous protein (CHOP), a ubiquitous 
transcription factor known to have a regulatory role in the crosstalk 
between autophagy and apoptosis.20 Our results therefore establish 
a vital role for PLP2 in promoting GBM growth and as a potential 
therapeutic target.
2  | RESULTS
2.1 | PLP2 overexpression is related to glioma 
tumour grade and patient prognosis
We first examined the levels of PLP2 expression in human glioma 
samples by analysing publicly available datasets from Rembrandt, 
The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome 
Atlas (CGGA). PLP2 was significantly up-regulated in GBMs com-
pared with low-grade gliomas (Figure 1A, P < .001), as shown pre-
viously.21 To further determine whether PLP2 expression was 
associated with aggressive clinicopathological characteristics, PLP2 
immunohistochemical (IHC) staining was performed on 72 paraf-
fin-embedded glioma tissue samples, including grade II (n = 16), III 
(n = 21) and IV (n = 35) brain tumour samples and normal brain tissue 
(n = 5) samples (Figure 1B). Quantitative analyses of mean PLP2 IHC 
staining scores showed that the PLP2 levels increased with disease 
grade (Figure 1C). Next, we performed Western blot analysis to de-
termine PLP2 protein levels in normal human astrocytes (NHA) and 
human GBM cell lines U87, A172, U251 and T98. All cell lines dis-
played higher PLP2 protein levels compared with NHAs (Figure 1D). 
Furthermore, based on Kaplan-Meier analysis of publicly available 
datasets (Rembrandt, TCGA and CCGA), high PLP2 expression pre-
dicted a shorter overall patient survival (Figure 1E). Taken together, 
these results indicate that PLP2 has an important role in glioma 
progression.
2.2 | Down-regulation of PLP2 inhibits cell 
proliferation in glioma cells
Several reports have shown that PLP2 is highly expressed in extrac-
ranial cancers where it has been shown to promote tumour growth 
and metastasis.4,22,23 To assess the biological role of PLP2 in glioma, 
we knocked down PLP2 expression in U87 and U251 GBM cells, 
using two small interfering RNAs (siPLP2-1 and siPLP2-2). Significant 
knockdown of PLP2 expression levels was obtained (Figure 2A and 
Figure S2A). Knockdown with siPLP2 also inhibited cell proliferation 
in both cell lines, as assessed in growth curves generated using the 
CCK-8 assay (Figure 2B and Figure S2B). These results were veri-
fied using EdU incorporation, which revealed reduced proliferation 
in U87 and U251 transfected with siPLP2 compared with controls 
(Figure 2C,D).
2.3 | Down-regulation of PLP2 induces ER 
stress and promotes apoptosis mediated in part 
by CHOP
Reduced PLP2 expression has previously been shown to in-
crease ER stress-induced neuronal apoptosis.7 To study potential 
changes in ER structures, we performed transmission electron mi-
croscopy (TEM) on U87 and U251 cells transfected with siPLP2 
for 48 hours. The lumen of the ER was markedly dilated and frag-
mented in siPLP2-treated cells compared with the control siNC 
transfected cells (Figure 3A and Figure S3A). To examine these 
changes at the molecular level, we performed Western blotting 
for ER stress-related proteins in siPLP2 transfected cells rela-
tive to controls. Levels of ER stress-related proteins, including 
phosphorylated protein kinase-like endoplasmic reticulum kinase 
(p-PERK), phosphorylated inositol requiring enzyme 1 (p-IRE1α), 
phosphorylated eukaryotic initiation factor 2 (p-eIF2α), CCAAT-
enhancer-binding protein homologous protein (CHOP) and glucose 
regulated protein 78 (GRP78), were increased in both U87- and 
U251-siPLP2 cells compared with levels in U87- and U251-siNC 
cells (Figure 3B).
Next, we used flow cytometry to determine whether PLP2 
knockdown induced apoptosis. SiPLP2 knockdown in both cell lines 
induced apoptosis in both early (annexin V+/PI−) and late (annexin 
V+/PI+) stage apoptosis (Figure 3C,D; Figures S3B,C). We confirmed 
these results using Western blot analyses of apoptosis-related mark-
ers. The levels of cleaved-caspase 9, cleaved-caspase 3 and cleaved-
PARP were up-regulated in U87- and U251-siPLP2-1 after 48 hours 
(Figure 3E).
A link between ER stress and apoptosis has been demonstrated 
previously,24,25 and a role for CHOP in ER stress-induced apoptosis 
has been established.26 To determine whether apoptosis resulted 
from ER stress, we used two siRNAs to suppress the expression of 
CHOP in U87 cells infected with a lentiviral shRNA construct tar-
geting PLP2. Expression of PLP2 in U87-shPLP2 (and U251-shPLP2) 
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was significantly down-regulated compared to expression in U87-
shNC (and U251-shNC), as assessed by Western blot (Figure S1). 
Cleaved-caspase 3 and cleaved-PARP expression in U87-shPLP2 
cells transfected with siCHOP did not increase to the levels ob-
served in U87-shPLP2 transfected with siNC (Figure 3F and Figure 
S3D). Collectively, these data show that down-regulation of PLP2 
expression induces ER stress and promotes apoptosis which is par-
tially dependent on CHOP in glioma cells.
2.4 | Down-regulation of PLP2 also induces 
autophagy in glioma cells
Previous studies have suggested that ER stress may induce au-
tophagy in various cancers.24,27,28 We therefore determined 
whether PLP2 knockdown was able to induce autophagy in the U87 
and U251 cells. Transmission electron microscopy is commonly used 
to identify the formation of autophagosomes, which is characterized 
by their double-membrane structures. Autophagosomes were quan-
tified using TEM and demonstrated that production of autophago-
somes was significantly increased in both U87- and U251-siPLP2 
cells compared with siNC-transfected cells (P < .001; Figure 4A,B; 
Figure S3A).
Levels of classical markers associated with autophagy were 
also assessed in U87- and U251-siPLP2 cells by Western blot. PLP2 
knockdown led to increased ATG5 and an increased LC3B-II/LC3B-I 
ratio, but decreased P62. These results were consistent with en-
hanced autophagic flux (Figure 4C). To further confirm the relation-
ship between ER stress and autophagy induced by PLP2 knockdown, 
we examined expression of these protein markers for autophagy by 
Western blot in U87-shNC and U87-shPLP2 cells transfected with 
siNC or siCHOP. The absence of CHOP interfered with the increase 
in the LC3BII/LC3BI ratio and the reduced levels of p62 induced by 
shPLP2 (Figure 4D and Figure S4). In conclusion, down-regulation 
of PLP2 also induces autophagy which is mediated in part by ER 
stress-induced CHOP in glioma cells.
2.5 | Autophagy inhibition augments apoptotic cell 
death induced by PLP2 knockdown
The crosstalk between apoptosis and autophagy has been well dem-
onstrated in other studies.29,30 In order to determine whether PLP2 
knockdown-induced autophagy was cytoprotective or cytotoxic, au-
tophagy was inhibited pharmacologically using chloroquine (CQ). Cells 
were pre-treated with 10 µmol/L CQ or vehicle control for 1 hours 
F I G U R E  2   Down-regulation of 
PLP2 expression inhibits glioma cell 
proliferation. A, Western blot to confirm 
knockdown efficiency of PLP2 by siRNA 
in U87 and U251 cells. B, Cell viability as 
determined using the CCK-8 of U87 and 
U251 transfected with siPLP2 and the 
scrambled negative control, siNC. *P < .05, 
**P < .01 and ***P < .001. C, Fluorescence 
microscopy of EdU incorporation in U87 
and U251-siPLP-1,2 siRNAs. Pollo 567 
(red colour) detects EdU, while DAPI (blue 
colour) stains nuclei Scale bar = 50 μm. 
D, Statistical analysis of the number of 
EdU-positive cells for U87 and U251 cell 
lines transfected with siRNAs. All data 
are expressed as the mean ± SD of values 
from triplicate experiments. ***P < .001
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prior to transfection with siPLP2-1 for 48 hours. Treatment with CQ 
increased apoptosis in U87- and U251-siPLP2 cells as detected by flow 
cytometry (Figure 5A,B). Statistical analysis revealed that the percent-
ages of apoptotic cells were significantly increased in the siPLP2-1 + CQ 
group compared with the siPLP2-1+ vehicle control group (Figure 5C). 
Consistent with these data, the protein levels of cleaved-PARP were 
also increased in siPLP2-1/CQ-treated cells compared with siPLP2-1-
treated cells (Figure 5D). Taken together, our results demonstrate that 
inhibition of autophagy augments apoptotic cell death induced by 
PLP2 knockdown in U87 and U251 glioma cell lines.
2.6 | Down-regulation of PLP2 inhibits glioma 
growth in vivo
To assess the function of PLP2 in vivo, we established orthotopic 
tumour models by implanting U87-shNC, U87-shPLP2, U251-shNC 
and U251-shPLP2 cells intracranially into nude mice. Tumour sizes 
were decreased in both U87- and U251-shPLP2 cells compared 
to controls (Figure 6A,B). Overall survival of animals was also sig-
nificantly prolonged in shPLP2 compared to shNC control groups 
(P < .01, P < .001, Figure 6C).
Immunohistochemical staining was performed on sections from 
U87-shNC and U87-shPLP2 xenografts to determine levels of PLP2, 
Ki-67 (a marker for proliferation) and cleaved-caspase 3 (a marker 
apoptosis). Levels of PLP2 and Ki-67 were decreased whereas levels 
of cleaved-caspase3 were increased in U87-shPLP2 xenografts com-
pared with U87-shNC xenografts (Figure 6D,E).
3  | DISCUSSION
PLP2 has previously been identified as a protein enriched in the co-
lonic epithelium.31 PLP2 contains four putative membrane-spanning 
F I G U R E  3   Down-regulation of 
PLP2 expression induces ER stress and 
promotes apoptosis through CHOP in 
glioma cells. A, Transmission electron 
microscopy images showing dilated ER 
in U87 and U251 cells transfected with 
siPLP2-1 for 48 h (right) compared with 
control siNC-transfected cells. Examples 
of ER are highlighted by white arrows. 
Scale bars = 1 μm. B, Western blots 
showing the levels of ER stress-related 
markers p-PERK, PERK, p-IRE1α, IRE1α, 
p-eIF2α, eIF2α, CHOP and GRP78 in 
U87- and U251-siNC or siPLP2-1 cells. C, 
Flow cytometry detecting apoptosis in 
U87- and U251-siNC or U251-siPLP2-1 at 
48 h after transfection. D, Quantification 
of the percentage of apoptotic cells 
analysed by flow cytometry. **P < .01 and 
***P < .001. E, Representative Western 
blots showing the levels of apoptosis-
related markers caspase-9, caspase 3 and 
PARP in U87- and U251-siNC or -siPLP2-1 
at 48 h after transfection. GAPDH is used 
as the control for loading. F, Western blots 
showing the levels of cleaved-caspase3 
and cleaved-PARP levels in U87-shNC and 
U87-shPLP2 cells transfected with siNC or 
siCHOP-1. GAPDH is used as the control 
for loading
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α-helices which multimerize to form ion channels.3 In cancer, PLP2 
has been reported to have an oncogenic role in melanoma, breast 
cancer and osteogenic sarcoma.4-6 In the present study, we found 
that PLP2 was highly expressed in high-grade gliomas relative to low-
grade gliomas and normal brain tissues based on data from three 
publicly available databases and in our own cohort of clinical sam-
ples. Moreover, high PLP2 expression was associated with poor pa-
tient survival.
We further show that down-regulation of PLP2 inhibits the pro-
liferation of glioma cells in vitro. Moreover, its inhibition also causes 
reduced intracranial tumour growth in vivo which leads to enhanced 
overall survival in animals. Our work therefore identifies PLP2 as a 
potential oncogene in glioma progression and provides a putative 
rationale for using the protein as a prognostic marker, or as a tar-
get in treatment of the disease. A prior study has also suggested an 
oncogenic role for PLP2 in glioma.21 However, our study is the first 
to establish that PLP2 down-regulation triggers ER stress-induced 
apoptosis and autophagy.
When ER stress is excessive and prolonged, morphological 
changes are apparent in the ER, and cells will eventually undergo 
apoptosis.32,33 A previous study has shown that PLP2 regulates cel-
lular responses to stimuli that converge towards the ER stress path-
way, thus providing strong evidence that reduced PLP2 expression 
increases susceptibility to ER stress.7 Also, it is well established that 
F I G U R E  4   Down-regulation of 
PLP2 expression induces autophagy in 
glioma cells. A, Transmission electron 
microscopy images showing formation 
of autophagosomes in U87- and U251-
siPLP2-1 (right) or -siNC (left) cells at 
48 h after transfection. Representative 
autophagosomes are highlighted with 
white arrows. Scale bars = 1 μm. B, 
Statistical analysis based on the number of 
autophagosomes per cell. Data are shown 
as the mean ± SD. **P < .01. C, Western 
blot analysis to detect autophagy-related 
markers ATG5, P62 and LC3B in U87- and 
U251-siNC or -siPLP2-1 cells. D, Western 
blot analysis to detect LC3B and p62 
levels in U87-shNC and U87-shPLP2 cells 
after transfection with siNC or siCHOP-1 
at 48 h
F I G U R E  5   Autophagy inhibition 
augments apoptotic cell death induced 
by PLP2 knockdown. A and B, Flow 
cytometric analysis using annexin V and 
PI staining to determine apoptosis in 
U87 and U251 cells pre-treated with the 
autophagy inhibitor CQ for 1 h or vehicle 
control, followed by transfection with 
siNC or siPLP2-1. C, Quantification of the 
percentage of apoptotic cells analysed by 
flow cytometry in treated U87 and U251 
cells. Data are shown as the mean ± SD. 
**P < .01 and ***P < .001. D, Western 
blot analysis to detect cleaved-PARP 
and LC3B levels in U87 and U251 cells 
pre-treated with the autophagy inhibitor 
CQ or vehicle control for 1 h followed by 
transfection with siNC or siPLP2-1
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CHOP and GRP78, which can be regarded as ER stress markers, play 
an important role in ER stress.34 In the present work, TEM demon-
strated that PLP2 knockdown results in less distinct ER morphology, 
a significant up-regulation of apoptosis-related markers, and in-
creased expression of ER stress-related proteins. In addition, CHOP 
knockdown partially reversed apoptosis induced by PLP2 silencing, 
as shown by activation of the PERK-eIF2α-CHOP pathway.
Autophagy may also be induced by ER stress in gliomas.35,36 In 
our study, the LC3BII/LC3BI ratio and levels of ATG5 were increased 
while p62 was decreased in our glioma cell lines transfected with 
siPLP2. These results are consistent with an increase in autophagy 
flux. Furthermore, autophagy flux induced by PLP2 knockdown was 
partially reversed via CHOP silencing, indicating that autophagy is 
also linked to ER stress induction. Our results further show that the 
use of CQ to inhibit autophagy pharmacologically increased apop-
tosis in the PLP2-silenced cells. These results suggested a possible 
augmentation of PLP2 knockdown-induced apoptosis through inhi-
bition of autophagy.
In summary, we have shown that down-regulation of PLP2 in-
creased ER stress-induced apoptosis, and cotreatment with an 
autophagy inhibitor further reduced tumour cell survival in vitro. 
Expression levels of PLP2 may thus be used as a potential future clin-
ical biomarker in GBM, and combined use of PLP2 down-regulation 
with autophagy inhibition may have a therapeutic advantage in GBM 
treatment. However, more studies on the molecular mechanisms un-
derlying PLP2 activity in glioma are warranted before translation of 
the strategy into clinical practice.
4  | MATERIAL S AND METHODS
4.1 | Ethics statement
All experiments performed with human samples were approved by 
the Research Ethics Committee of Shandong University. Informed 
written consent was obtained from all participants. All animal stud-
ies and procedures were approved by the Institutional Animal Care 
and Use Committee (IACUC) of Shandong University.
4.2 | Cell lines and cultures
Human glioma cell lines, U87, A172, U251 and T98, were purchased 
from the Chinese Academy of Sciences Cell Bank. Normal human 
astrocytes (NHA) were kindly provided by Prof. Rolf Bjerkvig, the 
Department of Biomedicine, the University of Bergen, Norway. 
F I G U R E  6   Down-regulation of PLP2 
inhibits glioma cell growth in vivo. A, 
Representative images of haematoxylin 
and eosin-stained sections from the brains 
of nude mice implanted intracranially 
with U87-shNC, U87-shPLP2, U251-
shNC or U251-shPLP2 cells. Scale 
bar = 2 mm. B, Mean relative tumour 
sizes in the brains of nude mice implanted 
intracranially with U87-shNC, U87-
shPLP2, U251-shNC or U251-shPLP2 
cells. C, Kaplan-Meier survival analysis of 
overall survival, and log-rank analysis to 
assess the statistical significance of the 
differences. D, Representative images of 
immunohistochemical staining for PLP2, 
Ki-67 and cleaved-caspase3 expression 
in xenograft sections from mice injected 
with U87-shNC or U87-shPLP2 cells. Scale 
bar = 100 μm. E, Graphic representation 
of IHC scoring of PLP2, Ki-67 and 
cleaved-caspase3 expression in xenograft 
sections. All data are presented as the 
mean ± SD, **P < .01, ***P < .001
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Cells were cultured in Dulbecco's modified Eagle's medium (DMEM, 
SH30022.01B, Thermo Fisher Scientific) supplemented with 10% 
foetal bovine serum (10082147 HyClone, GE Healthcare Life 
Sciences) at 37°C in a humidified incubator containing 5% CO2.
4.3 | Immunohistochemistry
Sections (4 μm) were cut from paraffin-embedded human and mouse 
tissues and mounted onto microscope slides. The slides were put into 
a glass container containing 10 mmol/L citric acid buffer (pH 7.2), 
and heat-induced epitope retrieval was performed in a microwave. 
The sections were blocked with goat serum, incubated with primary 
antibodies at 4°C overnight (PLP2, 1:200, Ki67, 1:300, Cleaved-
caspase3, 1:300, Cell Signaling Technology), rinsed with PBS and 
incubated with poly-HRP secondary antibodies for 30 minutes at 
room temperature (RT). Visualization was achieved using diamin-
obenzidine as the substrate, and slides were counterstained with 
Mayer's haematoxylin. Normal mouse serum was used as a negative 
control. Staining of cancer cells was scored as follows: 0, no stain-
ing; 1, weak staining in <50% cells; 2, weak staining in ≥50% cells; 
3, strong staining in <50% cells; and 4, strong staining in ≥50% cells.
4.4 | Western blot analysis
Cells were harvested, rinsed with cold PBS, and lysed using RIPA buffer 
containing a protein inhibitor cocktail (Thermo Fisher Scientific). 
Protein lysates (20 µg) were electrophoresed on 10% SDS-PAGE 
and transferred onto polyvinylidene difluoride (PVDF) membranes 
(ISEQ00010 0.22 μm, Millipore). Membranes were blocked in 5% 
skim milk blocking buffer for 1 hour at RT with 5% skim milk in TBST 
(20 mmol/L Tris-HCL (pH 8.0), 137 mmol/L NaCl and 0.1% Tween-20 
(or with 5% BSA in TBST for phospho-proteins) and incubated with 
primary antibodies overnight at 4°C. Membranes were incubated with 
the following antibodies: PLP2, p-IRE1α (Ser724, Abcam), ACTB, p-
PERK (Thr 980), PERK, IRE1α, p-eIF2α (Ser51), eIF2α, CHOP, GRP78, 
cleaved-caspase9, caspase9, cleaved-caspase3, caspase3, cleaved-
PARP, PARP, ATG5, P62, LC3B, GAPDH (Cell Signaling Technology). 
For detection, membranes were washed with TBST and incubated 
with the appropriate horseradish peroxidase (HRP)-conjugated sec-
ondary antibodies, antimouse immunoglobulin G (IgG) or anti-rabbit 
IgG (1:5000, Santa Cruz Biotechnology) for 1 hour at RT. The protein 
bands were visualized using Millipore's enhanced chemiluminescence 
(ECL) and detection system (ChemiDoc Touch, Bio-Rad). Bands were 
quantified and normalized relative to the loading control. Fold differ-
ences are labelled under each image.
4.5 | Small interfering RNA transfections
U87 and U251 cells were transfected with gene-specific siRNAs or 
negative control siRNA, synthesized by GenePharma, for 48 hours 
using Lipofectamine 2000 (Thermo Fisher Scientific, 11668-027) ac-
cording to the manufacturer's protocol. Cells were seeded at a den-
sity of 3 × 105 cells/well in 6-well plates. The siRNA duplexes were 
transfected into cells when the cells were 70-80% confluent. The 






Western blot analysis was used to evaluate siRNA knockdown 
efficiency.
4.6 | Cell viability and proliferation assays
The Cell Counting Kit-8 (CCK-8, CK04-500, Dojindo) was used to 
assess cell viability. Cells (1.0 × 104 cells/well) were seeded into 
96-well plates and incubated at 37°C overnight. After treatment, 
10 μL of CCK-8 in 100 μL of serum-free DMEM was added to re-
place the original medium. Cells were then incubated for an ad-
ditional 4 hours at 37°C. The optical absorbance at 450 nm was 
detected using a microplate reader (Bio-Rad). Proliferation was as-
sessed using the EdU incorporation assay according to the manu-
facturer's protocol (C103103, Ribobio). Briefly, cells were seeded 
onto 24-well plates at a density of 5.0 × 104 cells per well. After 
treatment, EdU was incorporated into proliferating cells, which 
is detected through a catalysed reaction with a fluorescently la-
belled azide. Labelled cells were examined under fluorescence 
microscopy, and the number of EdU-positive cells was counted in 
three random fields.
4.7 | Transmission electron microscopy (TEM)
Cells were fixed with 4% glutaraldehyde and post-fixed with 1% 
OsO4 in 0.1 mol/L cacodylate buffer containing 0.1% CaCl2 at 4°C 
for 2 hours. Samples were stained with 1% Millipore-filtered uranyl 
acetate, dehydrated in increasing concentrations of ethanol, and in-
filtrated and embedded in epoxy resin. Ultrathin sections were cut 
and stained with uranyl acetate and lead citrate. Electron photomi-
crographs were obtained, using a transmission electron microscope 
(JEM-1200EX II, JEOL).
4.8 | Apoptosis assay
Cells seeded in 6-well plates were detached with 0.25% trypsin, 
washed, resuspended in binding buffer and incubated with annexin 
V-FITC antibody (BD Biosciences) according to the manufacturer's 
instructions. Apoptotic cells were detected by flow cytometry 
(ACEA Biosciences), and the corresponding results were analysed 
using the software Flowjo, version 7.6.5, (Tree Star).
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4.9 | Lentiviral transduction
Lentiviral vectors expressing human shRNA targeting PLP2 (shPLP2, 
LV2017-18615, GenePharma Shanghai) or scrambled-control (shNC) 
were used to generate stable cell clones expressing shPLP2 or a 
nonspecific shRNA as the control. Transfected clones were selected 
using 1 mg/mL of puromycin (Selleckchem). Western blot analysis 
was used to evaluate shRNA knockdown efficiency.
4.10 | Intracranial xenograft model
Twenty-four athymic, male mice (4 weeks old, 20-30 g; Shanghai 
SLAC Laboratory Animal Co., Ltd) were randomly divided into the 
following four groups: U87-shNC (n = 6), U87-shPLP2 (n = 6), U251-
shNC (n = 6), and U251-shPLP2 (n = 6). The mice were anesthetized 
with chloral hydrate and secured on a stereotactic frame. A longi-
tudinal incision was made in the scalp and a 1 mm-diameter hole 
was drilled 2.5 mm lateral to the bregma. Cells (2 × 105) in 20 μL of 
serum-free DMEM were implanted 2.5 mm into the right striatum 
using a Hamilton syringe. Animals which displayed symptoms such 
as severe hunchback posture, apathy, decreased motion or activity, 
dragging legs, or drastic loss of body weight were euthanized by cer-
vical dislocation. Excised tumour tissues were formalin-fixed, par-
affin-embedded, and sectioned. Sections were either stained with 
haematoxylin and eosin (HE) or used for IHC. The relative tumour 
size was calculated as 0.5 × A × B2, where A represents the length 
of the tumour, and B represents the width of the tumour obtained 
from HE sections.
4.11 | Statistical analysis
All statistical analyses and experimental graphs were performed 
using GraphPad Prism 5 software. The results are presented as the 
mean ± the standard deviation (SD). Mean values were compared 
using Student's t test for paired data. Survival curves were estimated 
with the Kaplan-Meier method and compared using the log-rank 
test. All in vitro experiments were repeated independently at least 
three times. All tests were two-sided, and P-values determined from 
different comparisons <.05 were considered statistically significant 
and are indicated as follows: ns-not significant, *P < .05, **P < .01, 
***P < .001.
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